Related Experiment Video
Updated: May 30, 2026
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Practical considerations in ovarian cancer chemotherapy
Mihaela Cristea1, Ernest Han, Lennie Salmon
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd, Duarte, CA 91010, USA.
Therapeutic Advances in Medical Oncology
|July 27, 2011
Summary
Epithelial ovarian cancer treatment has evolved. Intraperitoneal chemotherapy shows survival benefits over intravenous, despite administration challenges.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Clinical Trials
Background:
- Epithelial ovarian cancer is a leading cause of cancer death in women.
- Standard treatment combines surgery and chemotherapy, typically intravenous platinum and taxane.
- Recent advances have explored alternative chemotherapy administration routes.
Purpose of the Study:
- To review the evolution of chemotherapy for epithelial ovarian cancer.
- To discuss current management strategies and considerations.
- To highlight the benefits and challenges of intraperitoneal chemotherapy.
Main Methods:
- Review of randomized phase III clinical trials.
- Analysis of survival data comparing treatment modalities.
- Discussion of clinical practice guidelines and expert opinion.
Main Results:
- Three major trials show improved survival with intraperitoneal chemotherapy versus intravenous.
- Intraperitoneal chemotherapy offers a significant survival advantage.
- Barriers and controversies exist regarding intraperitoneal chemotherapy administration.
Conclusions:
- Intraperitoneal chemotherapy represents a significant advancement in ovarian cancer treatment.
- Further research and clinical strategies are needed to overcome administration barriers.
- Optimizing chemotherapy delivery is crucial for improving patient outcomes in ovarian cancer.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Nursing Ethical Principles II
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...